BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32224719)

  • 1. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.
    Frilling A; Clift AK; Frampton AE; Bomanji J; Kaemmerer D; Al-Nahhas A; Alsafi A; Kidd M; Modlin IM; Hoersch D; Baum RP
    Int J Med Sci; 2021; 18(10):2166-2175. PubMed ID: 33859524
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort.
    Bösch F; Bruewer K; D'Anastasi M; Ilhan H; Knoesel T; Pratschke S; Thomas M; Rentsch M; Guba M; Werner J; Angele MK
    Surgery; 2018 Nov; 164(5):1093-1099. PubMed ID: 30076029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis.
    Fata CR; Gonzalez RS; Liu E; Cates JM; Shi C
    Am J Surg Pathol; 2017 Jan; 41(1):128-133. PubMed ID: 27684993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
    Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
    World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.
    Zaidi MY; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Makris E; Rocha F; Crown A; Idrees K; Marincola Smith P; Nathan H; Beems M; Abbott D; Barrett JR; Fields RC; Davidson J; Cardona K; Maithel SK
    JAMA Surg; 2019 Feb; 154(2):134-140. PubMed ID: 30383112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
    Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
    Huffman BM; Jin Z; Yadav S; Patel S; Nagorney DM; Truty MJ; McWilliams RR; Halfdanarson TR; Mahipal A
    Clin Colorectal Cancer; 2019 Sep; 18(3):218-225. PubMed ID: 31178274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.
    Taghipour Zahir S; Heidarymeybodi Z; AleSaeidi S
    Int J Surg Oncol; 2019; 2019():2912361. PubMed ID: 31186956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
    Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
    Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
    Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
    Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors.
    Gonzalez RS; Cates JMM; Shi C
    Mod Pathol; 2018 Oct; 31(10):1560-1566. PubMed ID: 29795438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
    Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
    J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
    Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
    Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases.
    Manguso N; Nissen N; Hendifar A; Harit A; Mirocha J; Friedman M; Lipshutz HG; Amersi F
    J Surg Oncol; 2019 Nov; 120(6):926-931. PubMed ID: 31396982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
    Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
    J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
    Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
    Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.